Riix halkan haddii kani yahay war-saxaafadeedkaaga!

Daawo Cusub Oo Ka Hortaga Fayraska Oselavir Oo Shiinaha Ka Bilawday

Written by editor

Hetero, oo ah hay'ad caalami ah oo caan ah oo isku dhafan dawooyinka iyo Shenzhen Beimei Pharmaceuticals ayaa si wada jir ah ugu dhawaaqay inay heleen shatiga dawooyinka soo dejinta ee Oseltamivir phosphate oo hoos timaada magaca astaanta Oselavir® oo ka socota maamulaha daroogada Shiinaha, Maamulka Alaabooyinka Caafimaadka Qaranka (NMPA).

Print Friendly, PDF & Email

Oseltamivir phosphate waa daawada fayruska ka hortagta ee loo isticmaalo daawaynta infekshanka hargabka degdega ah ee degdega ah ee dadka waaweyn, dhalinyarada iyo carruurta (≥2 toddobaad jir ah). Oselavir® waxaa laga heli doonaa Shiinaha qaabka qiyaasta - 12.5ml: 75mg budada ah ee joojinta afka. 

WHO waxay ku qiyaastay in hargabka xilliyeedka ahi uu sababi karo 290,000-650,000 dhimasho sannad kasta sababo la xiriira cudurrada neef-mareenka oo keliya. Qiyaasta laguma xisaabtamin dhimashada cudurrada kale sida cudurrada wadnaha iyo xididdada dhiigga, kuwaas oo noqon kara kuwo la xiriira hargabka1.

Dr. Vamsi Krishna Bandi, Agaasimaha Maamulka, Hetero Group of Companies ayaa yiri, "Waan ku faraxsanahay in Hetero oo iskaashi la leh Shenzhen Beimei Pharmaceuticals, Shiinaha, ay heshay ogolaanshaha Oselavir® (Oseltamivir) ee Shiinaha. Tani waa oggolaanshaha badeecada ee ugu horreysay ee Hetero ee Shiinaha, waxaana naga go'an inaan keeno alaabooyin badan Shiinaha mustaqbalka dhow."

Ms. Guangmei Wu, Madaxweynaha iyo maamulaha Shenzhen Beimei Pharmaceuticals ayaa yiri, "Iyada oo is-aaminaad iyo taageero u dhexeeya kooxaha Beimei iyo Hetero, Oselavir® waxaa laga bilaabay Shiinaha sida ugu horeysay ee Shiinaha ee Oseltamivir la ansixiyay ee foomka qiyaasta gaarka ah ee carruurta. Waxaan u mahadcelinayaa kooxda Hetero dadaalkooda iyo dadaalkooda ku aaddan dhammaan habka horumarinta alaabta, codsiga diiwaangelinta iyo diyaarinta bilowga Oselavir®. Waxaan rajeyneynaa inaan ku sahamno alaabooyin badan oo Hetero ah oo loogu talagalay daryeelka caafimaadka carruurta ee caalamiga ah mustaqbalka."

Print Friendly, PDF & Email

War ku saabsan qoraaga

editor

Tifatiraha guud waa Linda Hohnholz.

Leave a Comment